Compare Cassava Sciences Inc (FLNA) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.63. The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | VTIP | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | — |
52-Week High | $4.64 | $50.75 |
52-Week Low | $1.09 | $49.39 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $49.63, showing minimal daily movement. Technical indicators are bearish overall, with moving averages signaling a downtrend. Recent news highlights its role as an inflation hedge, with institutional buying interest noted. Financial ratios are not applicable as it is a bond ETF tracking TIPS.
The outlook for VTIP is tied to inflation trends and Federal Reserve policy. It offers protection against rising prices but faces headwinds if inflation moderates or rates stay high. Current sentiment is cautious, with the ETF positioned for investors seeking inflation-adjusted income in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
